In by S Segarra·2025—The Discovery, Characterization, and Quantification of BioactivePeptidesContained in Palbio Porcine Intestinal Mucosa Hydrolysate Products. by. Sergi Segarra.Read more the specialized field of biochemical research, the exploration of synthetic macrocyclic compounds has opened new doors for understanding molecular interactions. Among these, peptide CBO-P11 stands out as a subject of significant interest for researchers focusing on protein-ligand binding and signaling pathway modulation. As someone who follows advancements in laboratory-grade research compounds, I Oct 24, 2025—ERG-degrading Heliconpeptidespotently and durably reduced ERG protein levels —overexpressed in 40–50% of prostate cancers — showing in vivo Read more have found the technical profile of this 17-amino acid cyclic peptide to be remarkably precise for controlled experimental environments.
Technical Specifications and Structural Profile
Peptide CBO-P11 is formally recognized as a 17-amino acid cyclic peptide, often referred to as cyclo-VEGI. Its molecular architecture is derived from residues 79-93 of the Vascular Endothelial Growth Factor (VEGF). With a molecular formula of C94H145N29O25S and a molecular weight of 2113.43 g/mol, it serves as a highly specific tool in proteomics.
When analyzing the VEGF inhibitor CBO-P11, one must note its capacity to mediate binding to VEGFR-2. Structurally, the molecule is designed to block the interaction between growth factors and their receptors. This specificity is why the agent is used as targeting ligand for tumor angiogenesis in controlled *in vitro* models. Researchers often utilize this compound to study the mechanisms by which a molecule controls the biological activity of VEGF, essentially acting as a structural probe.
Experimental Applications and Utility
In my review of laboratory practices, I have observed that peptide CBO-P11 is frequently deployed in analytical biochemistry. It is primarily used for Phosphorylation & Dephosphorylation applications, where researchers track protein activation states. By inhibiting specific binding events, this cyclic peptide CBO-P11 allows for a clearer observation of downstream signaling cascades, such as the downregulation of Akt3.
For those looking to buy highly pure CBO-P In order to attach thepeptide CBO-P11onto nanoparticles, a functionalization of the original peptide is needed. Propargylamine was coupled to the glutamic 11, it is critical to verify the CAS No: 612096-46-5. High-quality samples are typically provided as a lyophilized powder, which requires storage at -20°C to maintain stability. Its solubi CBO-P11 | Tumor vascular targeting agent lity in DMSO makes it compatible with various buffer systems used in high-throughput proteomic approaches.
Advancements in Peptide Research
The field of peptides is currently undergoing a transformation, with researchers moving to explore AI-driven design, novel delivery methods & targeted therapy innovations. The P11 peptide is a classic example of how a small, synthetic macrocyclic structure can be functionalized—for instance, by coupling it to nanoparticles—to enhance its utility as a research probe.
Furthermore, the 17-amino acid cyclic peptide (CBO-P11) has b Structure and inhibitory effects on angiogenesis and tumor een instrumental in studies demonstrating how a compound is able to inhibit the intera VEGF Inhibitor, CBO-P11 - Calbiochem | 676496 ction between the growth factor and its receptor. Because it is a VEGF Inhibitor, CBO-P11 acts as a molecular "blocker," providing a baseline against which other novel angiogenesis inhibitors are measured. Whether examining technical guides on synthesis or reviewing proteomics data, the consistency of this molecule remains a benchmark in the study of receptor-ligand dynamics.
Conclusion
The study of peptide CBO-P11 continues to provide valuable insights into the regulation of vascular endothelial growth factors. As a research-grade tool, its ability to interfere with specific binding sites make CBO-P11 specifically binds to receptor of VEGFR-2 andis used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine s it an indispensable asset for those investigating complex protein signaling. By maintaining strict handling protocols—such as proper storage and precise solvent preparation—investigators can ensure the reliability of their data when using this potent inhibitor. The ongoing evolution of P11-based research highlights the enduring importance of well-characterized cyclic peptides in modern biochemical discovery.